Behind the news
This section aims to provide detailed and transparent overviews of issues relating to the TGA.
Articles that appear here may be of particular interest to the community, or in response to subjects that have received media attention.
If you would like to see particular issues addressed in this section, please let us know by emailing info@tga.gov.au or calling 1800 020 653.
26 November 2012
Cough and cold medicines for children - changes
Advice to consumers and health professionals on cough and cold medicines for children
16 October 2012
Concerns with urogynaecological surgical mesh implants
Urogynaecological surgical mesh implants are used in some surgical procedures to treat the symptoms of pelvic organ prolapse and stress urinary incontinence
16 October 2012
Urogynaecological surgical mesh implants - statement provided to the 7.30 Report (ABC) by the TGA
Statement provided to the 7.30 Report (ABC) by the TGA
30 August 2012
Registration of Mifepristone Linepharma (RU 486) and GyMiso (misoprostol)
The drugs for medical termination of pregnancy, Mifepristone Linepharma (RU 486) and GyMiso® (misoprostol), have been registered today by the TGA
3 August 2012
The TGA decision to ban DMAA
The TGA has banned the use of the chemical 1,3-dimethylamylamine (DMAA)
3 August 2012
Interpreting information on the Database of Adverse Event Notifications
TGA is concerned by a media story that may mislead consumers and could potentially discourage them from receiving influenza vaccinations
6 July 2012
Why hasn't the TGA taken Stilnox off the market?
As the medicines' watchdog, the TGA, has been closely monitoring the sleeping drug, zolpidem (Stilnox) for many years
9 December 2011
TGA committee members must declare conflict of interest
Members of TGA statutory expert advisory committees are required to declare any conflict of interest, whether financial or non-financial
18 November 2011
The regulation of medical devices
Information on the regulation of medical devices
8 July 2011
The TGA and the USA FDA agree about problems at CSL Biotherapies
The TGA wishes to clarify some aspects of this action and what it means for public safety
30 June 2011
Evaluation of a new medicine - The TGA's lifecycle approach to regulation
The TGA aims to ensure that the community has access to therapeutic advances within a reasonable timeframe
24 June 2011
CSL Biotherapies: 'Warning Letter' issued by the United States' Food and Drug Administration
The United States' Food and Drug Administration (FDA) has issued a 'Warning Letter' to CSL Biotherapies (CSL) following their audit of CSL's manufacturing facility
16 May 2011
Recall of DePuy Orthopaedics ASR hip replacement device
Australia was the first country in the world to take regulatory action to ensure the removal of the DePuy ASR hip replacements from the market
13 May 2011
Complementary medicines: the regulatory framework
How complementary medicines are regulated in Australia
8 October 2010
Overview of vaccine regulation and safety monitoring and investigation into adverse events following 2010 seasonal influenza vaccination in young children
In Australia, vaccines and other prescription medicines are regulated by the TGA in accordance with the provisions of the Therapeutic Goods Act 1989.
Web page last updated: Wednesday, 29 August 2012
URL: http://www.tga.gov.au/newsroom/btn.htm